B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Positive 65.1%

Neg 0% Neu 0% Pos 65.1%

B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $27.